Condition: Healthy Subjects (HS) · Obese Adult Participants at Risk of Cardiovascular Disease · Sponsor: InSilico Medicine Hong Kong Limited
This is a single center, phase 1, randomized, double-blind, placebo-controlled sequential study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of ISM8969 in healthy adults and elderly participants and obese adult participants at risk of cardiovascular disease.
This description comes directly from the study's public registry record.
Johnny Ju · +86 021-50831718 · Insilico-Clinicaltrial@insilico.ai
Always discuss trial participation with your own doctor first.
| Nucleus Network Pty Ltd. | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07581431